Toleranzia AB (TOL.ST)
SEK 0.61
(0.33%)
SEK 0.61
(0.33%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -17.45 Million SEK | 47.25% |
| 2022 | -33.08 Million SEK | 56.13% |
| 2021 | -75.42 Million SEK | -78.31% |
| 2020 | -42.3 Million SEK | -111.48% |
| 2019 | -20 Million SEK | -29.37% |
| 2018 | -15.46 Million SEK | -160.33% |
| 2017 | -5.93 Million SEK | 57.97% |
| 2016 | -14.13 Million SEK | 34.63% |
| 2015 | -21.61 Million SEK | -3462.66% |
| 2014 | 642.78 Thousand SEK | 726.65% |
| 2013 | 77.75 Thousand SEK | 104.73% |
| 2012 | -1.64 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -9.74 Million SEK | 44.16% |
| 2024 Q3 | 6.46 Million SEK | 381.73% |
| 2024 Q2 | -2.29 Million SEK | 76.47% |
| 2023 Q2 | 147 Thousand SEK | 100.71% |
| 2023 Q1 | -20.75 Million SEK | 37.29% |
| 2023 FY | -17.45 Million SEK | 47.25% |
| 2023 Q4 | -17.45 Million SEK | 44.87% |
| 2023 Q3 | -31.66 Million SEK | -21638.1% |
| 2022 Q3 | -46.73 Million SEK | 9.57% |
| 2022 FY | -33.08 Million SEK | 56.13% |
| 2022 Q4 | -33.08 Million SEK | 29.2% |
| 2022 Q1 | -64.95 Million SEK | 13.89% |
| 2022 Q2 | -51.67 Million SEK | 20.44% |
| 2021 Q1 | -34.63 Million SEK | 18.11% |
| 2021 Q4 | -75.42 Million SEK | 11.53% |
| 2021 Q3 | -85.25 Million SEK | -215.8% |
| 2021 FY | -75.42 Million SEK | -78.31% |
| 2021 Q2 | -26.99 Million SEK | 22.06% |
| 2020 Q1 | -15.99 Million SEK | 20.01% |
| 2020 Q2 | -10.15 Million SEK | 36.54% |
| 2020 Q3 | -46.48 Million SEK | -357.79% |
| 2020 Q4 | -42.3 Million SEK | 8.99% |
| 2020 FY | -42.3 Million SEK | -111.48% |
| 2019 Q2 | -10.32 Million SEK | 22.02% |
| 2019 Q1 | -13.24 Million SEK | 14.37% |
| 2019 Q4 | -20 Million SEK | -136.27% |
| 2019 Q3 | -8.46 Million SEK | 18.01% |
| 2019 FY | -20 Million SEK | -29.37% |
| 2018 Q2 | -19.51 Million SEK | 20.55% |
| 2018 Q4 | -15.46 Million SEK | 12.39% |
| 2018 FY | -15.46 Million SEK | -160.33% |
| 2018 Q3 | -17.64 Million SEK | 9.56% |
| 2018 Q1 | -24.56 Million SEK | -313.52% |
| 2017 Q1 | -11.87 Million SEK | 15.98% |
| 2017 FY | -5.93 Million SEK | 57.97% |
| 2017 Q2 | -10.02 Million SEK | 15.55% |
| 2017 Q4 | -5.93 Million SEK | 29.96% |
| 2017 Q3 | -8.48 Million SEK | 15.42% |
| 2016 Q1 | -20.24 Million SEK | 6.34% |
| 2016 FY | -14.13 Million SEK | 34.63% |
| 2016 Q3 | -16.29 Million SEK | 11.06% |
| 2016 Q2 | -18.31 Million SEK | 9.52% |
| 2016 Q4 | -14.13 Million SEK | 13.26% |
| 2015 Q1 | 207.21 Thousand SEK | -67.76% |
| 2015 FY | -21.61 Million SEK | -3462.66% |
| 2015 Q4 | -21.61 Million SEK | 0.0% |
| 2014 FY | 642.78 Thousand SEK | 726.65% |
| 2014 Q4 | 642.78 Thousand SEK | 0.0% |
| 2013 FY | 77.75 Thousand SEK | 104.73% |
| 2012 FY | -1.64 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | 9.302% |
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | 40.021% |
| BioGaia AB (publ) | -1.53 Billion SEK | 98.863% |
| Enzymatica AB (publ) | 17.73 Million SEK | 198.404% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | -205.3% |
| Gabather AB (publ) | -1.11 Million SEK | -1465.381% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | 198.694% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | 68.731% |
| Nanexa AB (publ) | -61.13 Million SEK | 71.451% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | -14.056% |
| ODI Pharma AB | -2.63 Million SEK | -561.661% |
| Orexo AB (publ) | 302.8 Million SEK | 105.764% |
| Probi AB (publ) | -275.85 Million SEK | 93.673% |
| Swedencare AB (publ) | 1.42 Billion SEK | 101.228% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 100.089% |
| Vivesto AB | -1.29 Million SEK | -1243.649% |